致心律失常性右心室心肌病心律失常风险预测模型的外部验证
本研究在北美和欧洲29个中心429例致心律失常性右心室心肌病(ARVC)患者中外部验证2019年开发的5年室性心律失常风险预测模型(ARVCrisk.com)。中位随访5.02年,24%患者发生持续性室性心律失常,模型区分度良好(C-index 0.70),校准斜率1.01。与三个已发表的ICD决策共识算法相比,该模型在35%风险阈值下净临床获益更优。
要点
- ARVC风险计算器外部验证区分度良好(C-index 0.70),校准良好。
- 相比三个ICD共识算法,风险计算器净临床获益更优。
- 支持用该模型辅助ARVC患者ICD植入的共享决策。
核心结论
- ARVC风险模型提供良好预后信息,优于其他已发表的ICD决策算法。
- 研究支持使用该模型促进ARVC患者一级预防ICD植入的共享决策。
研究设计与样本
- 回顾性多中心队列研究,纳入北美和欧洲29个中心的429例ARVC患者。
- 中位随访5.02年(范围2.05-7.90年),评估5年持续性室性心律失常风险。
主要发现
- 103例(24%)患者在诊断ARVC后中位随访5.02年内发生持续性室性心律失常。
- 外部验证区分度C-index为0.70(95%CI 0.65-0.75),校准斜率1.01(95%CI 0.99-1.03)。
关键数值与推荐
- 与心脏节律学会共识、国际工作组共识和美国心脏协会指南三个ICD决策算法相比,风险计算器在35%风险阈值以下净临床获益更优。
临床怎么用
- 可用ARVC风险计算器(ARVCrisk.com)评估5年室性心律失常风险,辅助ICD植入决策。
- 在共享决策中,该模型可能优于传统共识算法。
局限性
- 回顾性队列设计可能存在选择偏倚。
- 未报告模型在特定亚组中的表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Arrhythmogenic right ventricular cardiomyopathy (ARVC) causes ventricular arrhythmias (VAs) and sudden cardiac death (SCD). In 2019, a risk prediction model that estimates the 5-year risk of incident VAs in ARVC was developed (ARVCrisk.com). This study aimed to externally validate this prediction model in a large international multicentre cohort and to compare its performance with the risk factor approach recommended for implantable cardioverter-defibrillator (ICD) use by published guidelines and expert consensus. METHODS AND RESULTS: In a retrospective cohort of 429 individuals from 29 centres in North America and Europe, 103 (24%) experienced sustained VA during a median follow-up of 5.02 (2.05-7.90) years following diagnosis of ARVC. External validation yielded good discrimination [C-index of 0.70 (95% confidence interval-CI 0.65-0.75)] and calibration slope of 1.01 (95% CI 0.99-1.03). Compared with the three published consensus-based decision algorithms for ICD use in ARVC (Heart Rhythm Society consensus on arrhythmogenic cardiomyopathy, International Task Force consensus statement on the treatment of ARVC, and American Heart Association guidelines for VA and SCD), the risk calculator performed better with a superior net clinical benefit below risk threshold of 35%. CONCLUSION: Using a large independent cohort of patients, this study shows that the ARVC risk model provides good prognostic information and outperforms other published decision algorithms for ICD use. These findings support the use of the model to facilitate shared decision making regarding ICD implantation in the primary prevention of SCD in ARVC.
引用
- Jordà P, Bosman LP, Gasperetti A, et al. Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. Eur Heart J. 2022. PMID: 35766180. doi:10.1093/eurheartj/ehac289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。